NCT00159731

Brief Summary

The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2005

Geographic Reach
1 country

29 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 8, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 12, 2005

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
Last Updated

January 22, 2021

Status Verified

July 1, 2006

First QC Date

September 8, 2005

Last Update Submit

January 20, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Adverse events

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults with Type 1 or 2 diabetes
  • Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months

You may not qualify if:

  • Patients must not be in poor or unstable health.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Pfizer Investigational Site

Hot Springs, Arkansas, 71913, United States

Location

Pfizer Investigational Site

La Jolla, California, 92037, United States

Location

Pfizer Investigational Site

Torrance, California, 90502, United States

Location

Pfizer Investigational Site

Torrance, California, 90509, United States

Location

Pfizer Investigational Site

Denver, Colorado, 80218, United States

Location

Pfizer Investigational Site

Ocala, Florida, 34471, United States

Location

Pfizer Investigational Site

Ocala, Florida, 34474, United States

Location

Pfizer Investigational Site

Palm Beach Gardens, Florida, 33410, United States

Location

Pfizer Investigational Site

Sunrise, Florida, 33351, United States

Location

Pfizer Investigational Site

West Palm Beach, Florida, 33401, United States

Location

Pfizer Investigational Site

West Palm Beach, Florida, 33407, United States

Location

Pfizer Investigational Site

Boston, Massachusetts, 02115, United States

Location

Pfizer Investigational Site

Omaha, Nebraska, 68116, United States

Location

Pfizer Investigational Site

Omaha, Nebraska, 68131, United States

Location

Pfizer Investigational Site

Las Vegas, Nevada, 89102, United States

Location

Pfizer Investigational Site

Englewood, New Jersey, 07631, United States

Location

Pfizer Investigational Site

New Brunswick, New Jersey, 08903, United States

Location

Pfizer Investigational Site

Albany, New York, 12205, United States

Location

Pfizer Investigational Site

Rochester, New York, 14618, United States

Location

Pfizer Investigational Site

Rochester, New York, 14642, United States

Location

Pfizer Investigational Site

Greenville, North Carolina, 27834, United States

Location

Pfizer Investigational Site

Toledo, Ohio, 43623, United States

Location

Pfizer Investigational Site

Duncansville, Pennsylvania, 16635, United States

Location

Pfizer Investigational Site

Dallas, Texas, 75230, United States

Location

Pfizer Investigational Site

Dallas, Texas, 75246, United States

Location

Pfizer Investigational Site

Houston, Texas, 77030, United States

Location

Pfizer Investigational Site

San Antonio, Texas, 78229, United States

Location

Pfizer Investigational Site

Salt Lake City, Utah, 84108, United States

Location

Pfizer Investigational Site

Salt Lake City, Utah, 84132, United States

Location

Related Links

MeSH Terms

Interventions

Pregabalin

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2005

First Posted

September 12, 2005

Study Start

January 1, 2005

Study Completion

May 1, 2006

Last Updated

January 22, 2021

Record last verified: 2006-07

Locations